Sign inJoin waitlistJoin the waitlist

Babak Edraki

Accepting New Patients · John Muir Health

Credentials: · · · ·

History

John Muir Health
Present

Gynecologic Oncology
Yale Univ Sch of Med
1992–1995
Obstetrics and Gynecology
Stanford University Medical Center
1989–1992
Santa Clara Valley Healthcare
1988–1989
George Washington Univ Sch of Med
1984–1988

Research

Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor…
Journal of Clinical Oncology · 2018 · 400 citations
Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that…
Clinical Cancer Research · 2020 · 249 citations
Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition
Proceedings of the National Academy of Sciences of the United States of America · 2016 · 189 citations

PS
Peter Schwartz
5 papers
Alessandro Santin
3 papers
Dan-Arin Silasi
3 papers
Elena Ratner
3 papers
Masoud Azodi
3 papers
Natalia Buza
3 papers
Pei Hui
3 papers
Setsuko Chambers
3 papers
Angeles Secord
2 papers
Babak Litkouhi
2 papers
Dana Roque
2 papers
David O'Malley
2 papers

Clinical trials

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Site PI · Recruiting · Phase 3
NRG Oncology
2025–2034
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2022–2027
Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Site PI · Unknown · Phase 3
Gynecologic Oncology Group
2012